HOOKIPA Pharma Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Malte Peters

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris	16.88%
Dienstverband CEO	1.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyseartikel • Dec 21

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Unfortunately for some shareholders, the HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) share price has dived 26% in the last...

Analyseartikel • Nov 19

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Sep 27

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shareholders that were waiting for something to happen have been dealt a blow with...

Analyseartikel • Aug 13

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

To the annoyance of some shareholders, HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares are down a considerable 29% in the...

Analyseartikel • Jun 22

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have had a horrible month, losing 34% after a relatively good period...

Analyseartikel • Apr 28

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have continued their recent momentum with a 25% gain in the last month...

Analyseartikel • Mar 24

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

The analysts covering HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) delivered a dose of negativity to shareholders today, by...

Analyseartikel • Aug 11

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...

Analyseartikel • May 16

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...

Analyseartikel • Apr 26

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analyseartikel • Nov 19

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Shareholders in HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) may be thrilled to learn that the analysts have just delivered a...

Seeking Alpha • Jul 25

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Clinical-stage biotech HOOKIPA Pharma (NASDAQ:HOOK) announced on Monday that the FDA accepted its Investigational New Drug (IND) application for HB-300, an experimental therapy for metastatic castration-resistant prostate cancer. A Phase 1/2 trial for the treatment is expected to start by early next year. “FDA acceptance of our IND application for HB-300 is a key milestone as we expand and diversify our oncology pipeline and arenavirus platform from viral antigens to self-antigens,” Chief Executive Joern Aldag remarked. HB-300 is identified as an arenaviral immunotherapy designed to target two well-established antigens of prostate cancer, PAP and PSA. Parallelly, HOOKIPA (HOOK) announced that the FDA accepted the Drug Master File (DMF) to support the future submission of data specific to its replicating arenavirus platform. With the concurrent acceptance of DMF, “we have reduced cycle time between completion of preclinical studies and clinical entry of our pipeline projects,” Aldag added. Read: In April, HOOKIPA (HOOK) announced pre-clinical data supporting the potential of its arenaviral platform against various cancers.

Analyse CEO-vergoeding

Hoe is Malte Peters's beloning veranderd ten opzichte van HOOKIPA Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2025	n/a	n/a	-US$73m
Dec 31 2024	US$2m	US$281k	-US$44m
Sep 30 2024	n/a	n/a	-US$43m
Jun 30 2024	n/a	n/a	-US$49m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$232k	n/a	-US$82m

Compensatie versus markt: De totale vergoeding ($USD 1.67M ) Malte } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.55K ).

Compensatie versus inkomsten: De vergoeding van Malte is gestegen terwijl het bedrijf verliesgevend is.

CEO

Malte Peters (63 yo)

1.8yrs

Tenure

US$1,666,767

Compensatie

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Malte Peters	CEO, President & Director	1.8yrs	US$1.67m	geen gegevens
Mary Coelho	Executive VP	1.8yrs	US$1.08m	0.17% $ 25.4k
Daniel Pinschewer	Co-Founder & Member of Scientific Advisory Board	15.3yrs	geen gegevens	geen gegevens
Mark Winderlich	Chief Research & Development Officer	2.1yrs	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HOOK wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Malte Peters	CEO, President & Director	3.3yrs	US$1.67m	geen gegevens
Mary Coelho	Executive VP	3.1yrs	US$1.08m	0.17% $ 25.4k
Daniel Pinschewer	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul-Henri Lambert	Member of Scientific Advisory Board	no data	US$46.34k	geen gegevens
Sean Cassidy	Independent Director	1.8yrs	US$79.53k	0% $ 0
Igor Matushansky	Chairman of the Scientific Advisory Board	no data	US$1.42m	geen gegevens
Julie O'Neill	Independent Non-Executive Chair	7.5yrs	US$89.99k	0.0039% $ 590.8
David Kaufman	Independent Director	7.1yrs	US$81.32k	0.0036% $ 543.3

3.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HOOK wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/17 19:17
Aandelenkoers aan het einde van de dag	2026/05/15 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

HOOKIPA Pharma Inc. wordt gevolgd door 5 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Alec Stranahan	BofA Global Research
Swayampakula Ramakanth	H.C. Wainwright & Co.
Debjit Chattopadhyay	H.C. Wainwright & Co.

HOOKIPA Pharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

HOOKIPA Pharma Inc. Announces Board Changes

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Recent updates

HOOKIPA Pharma Inc. Files Form 15

HOOKIPA Pharma Inc.(NasdaqCM:HOOK) dropped from NASDAQ Composite Index

Consensus revenue estimates decrease by 10%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Poolbeg Pharma PLC (AIM:POLB) cancelled the acquisition of HOOKIPA Pharma Inc. (NasdaqCM:HOOK) in a reverse merger transaction.

New minor risk - Share price stability

Poolbeg Pharma PLC (AIM:POLB) entered into non-binding discussions to acquire HOOKIPA Pharma Inc. (NasdaqCM:HOOK) for $1.3 million in a reverse merger transaction.

Consensus EPS estimates fall by 57%

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

New major risk - Revenue and earnings growth

Price target decreased by 11% to US$38.75

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

Price target increased by 16% to US$43.50

Less than half of directors are independent

HOOKIPA Pharma Inc. Announces Board Changes

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Second quarter 2024 earnings: Revenues miss analyst expectations

HOOKIPA Pharma Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Consensus estimates of losses per share improve by 18%

Price target increased by 8.7% to US$50.00

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting

First quarter 2024 earnings released: EPS: US$0.11 (vs US$0.27 loss in 1Q 2023)

HOOKIPA Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

HOOKIPA Pharma Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

HOOKIPA Pharma Provides Non-Compliance Update

Price target decreased by 11% to US$4.17

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Consensus revenue estimates increase by 14%

Price target decreased by 7.6% to US$4.32

HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma Inc. to Report Q3, 2023 Results on Nov 09, 2023

Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

Price target increased by 16% to US$5.38

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates upgraded to US$1.09 loss

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma Inc. to Report Q1, 2023 Results on May 11, 2023

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Less than half of directors are independent

Price target decreased by 18% to US$4.64

Full year 2022 earnings: EPS and revenues exceed analyst expectations

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Appoints Katia Schlienger as Chief Medical Officer and Malte Peters to Board of Directors